FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3096473443> ?p ?o ?g. }

• W3096473443 endingPage "28332" @default.
• W3096473443 startingPage "28319" @default.
• W3096473443 abstract "Combination of drugs is extensively used to treat chronic inflammatory disease. Naringin (NAR), sulforaphane (SFN), and phenethyl isothiocyanate (PEITC) are nutraceuticals with promising anti-inflammatory properties. However, their clinical effectiveness gets hindered because of low aqueous solubility and poor bioavailability. In the current study, two combinations of liposome (NAR + SFN and NAR + PEITC) were prepared and studied thoroughly in different in vivo models of acute and chronic models of inflammation. The encapsulation efficiency of NAR, SFN, and PEITC in the combination liposomal formulations (CLFs) prepared with 1,2-dipalmitoyl-sn-glycero-3-phosphocholine/cholesterol/1,2-distearoyl-sn-glycero-3-phosphoethanolamine -020CN (15:4:1 M ratio) was determined to be 79.8 ± 4.2, 46.5 ± 3.6, and 78.5 ± 3.2%, respectively. The CLFs were characterized by differential scanning calorimetry, X-ray diffraction, dynamic light scattering, and Fourier transform infrared spectroscopy. The physicochemical results showed that the preparations were monodisperse (PDI 0.062–0.248) in water with an average size from 140.5 to 165.6 nm and a zeta potential of −47.3 to −53.3 mV. Dissolution studies in vitro showed a slower release of PEITC (>90%, 6 h) in comparison to that of SFN (3 h). Here, we are the first to report the antiarthritic activity of CLF of NAR + SFN and NAR + PEITC in the Freund’s complete adjuvant (FCA)-induced arthritic model. At an intraperitoneal dose (375 + 375 μg/mL) for 3 weeks, the NAR + PEITC liposome significantly improves both % paw edema and arthritic score compared to their free drug combinations in FCA rats. Most importantly, hematological and biochemical results showed improved anemic conditions with significant changes in the SGOT, SGPT, and ALP levels. The ELISA results showed similar trends of increased cytokine (IL-10) and decreased inflammation markers (TNF-α, IL-6, IFN-γ). Histological evaluations showing reduction in cell infiltration, pannus formation, and bone and cartilage destruction further confirm and validate the antiarthritic activity of the CLF. This comprehensive study reveals the effectiveness of combination liposomes of poorly soluble anti-inflammatory molecules (NAR, SFN, PEITC) in the treatment of arthritis." @default.
• W3096473443 created "2020-11-09" @default.
• W3096473443 creator A5000330321 @default.
• W3096473443 creator A5005030868 @default.
• W3096473443 creator A5030894364 @default.
• W3096473443 creator A5032763974 @default.
• W3096473443 creator A5034760600 @default.
• W3096473443 date "2020-10-26" @default.
• W3096473443 modified "2023-10-18" @default.
• W3096473443 title "Naringin in Combination with Isothiocyanates as Liposomal Formulations Potentiates the Anti-inflammatory Activity in Different Acute and Chronic Animal Models of Rheumatoid Arthritis" @default.
• W3096473443 cites W185057651 @default.
• W3096473443 cites W1863861988 @default.
• W3096473443 cites W1977467418 @default.
• W3096473443 cites W1978752121 @default.
• W3096473443 cites W1981819970 @default.
• W3096473443 cites W1989808058 @default.
• W3096473443 cites W1991774590 @default.
• W3096473443 cites W1991933724 @default.
• W3096473443 cites W1992993767 @default.
• W3096473443 cites W1998100638 @default.
• W3096473443 cites W1998346656 @default.
• W3096473443 cites W2008376262 @default.
• W3096473443 cites W2021367421 @default.
• W3096473443 cites W2035695365 @default.
• W3096473443 cites W2042536416 @default.
• W3096473443 cites W2044325823 @default.
• W3096473443 cites W2062394119 @default.
• W3096473443 cites W2062753270 @default.
• W3096473443 cites W2074438676 @default.
• W3096473443 cites W2079502732 @default.
• W3096473443 cites W2079628186 @default.
• W3096473443 cites W2095363290 @default.
• W3096473443 cites W2096795975 @default.
• W3096473443 cites W2113178669 @default.
• W3096473443 cites W2116978833 @default.
• W3096473443 cites W2126107019 @default.
• W3096473443 cites W2136909442 @default.
• W3096473443 cites W2145173391 @default.
• W3096473443 cites W2149026148 @default.
• W3096473443 cites W2155843895 @default.
• W3096473443 cites W2165002370 @default.
• W3096473443 cites W2166348180 @default.
• W3096473443 cites W2312937577 @default.
• W3096473443 cites W2315280595 @default.
• W3096473443 cites W2322047794 @default.
• W3096473443 cites W2555276433 @default.
• W3096473443 cites W2792731182 @default.
• W3096473443 cites W2800330801 @default.
• W3096473443 cites W2806417051 @default.
• W3096473443 cites W2884133105 @default.
• W3096473443 cites W2884459466 @default.
• W3096473443 cites W2900561361 @default.
• W3096473443 cites W2944137900 @default.
• W3096473443 cites W2980741583 @default.
• W3096473443 cites W2985331830 @default.
• W3096473443 cites W2995031212 @default.
• W3096473443 cites W3015526997 @default.
• W3096473443 cites W3033132837 @default.
• W3096473443 cites W3034517410 @default.
• W3096473443 cites W4206487879 @default.
• W3096473443 cites W4210968471 @default.
• W3096473443 doi "https://doi.org/10.1021/acsomega.0c04300" @default.
• W3096473443 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7860241" @default.
• W3096473443 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33553962" @default.
• W3096473443 hasPublicationYear "2020" @default.
• W3096473443 type Work @default.
• W3096473443 sameAs 3096473443 @default.
• W3096473443 citedByCount "31" @default.
• W3096473443 countsByYear W30964734432021 @default.
• W3096473443 countsByYear W30964734432022 @default.
• W3096473443 countsByYear W30964734432023 @default.
• W3096473443 crossrefType "journal-article" @default.
• W3096473443 hasAuthorship W3096473443A5000330321 @default.
• W3096473443 hasAuthorship W3096473443A5005030868 @default.
• W3096473443 hasAuthorship W3096473443A5030894364 @default.
• W3096473443 hasAuthorship W3096473443A5032763974 @default.
• W3096473443 hasAuthorship W3096473443A5034760600 @default.
• W3096473443 hasBestOaLocation W30964734431 @default.
• W3096473443 hasConcept C126322002 @default.
• W3096473443 hasConcept C150903083 @default.
• W3096473443 hasConcept C155672457 @default.
• W3096473443 hasConcept C171250308 @default.
• W3096473443 hasConcept C181389837 @default.
• W3096473443 hasConcept C185154212 @default.
• W3096473443 hasConcept C185592680 @default.
• W3096473443 hasConcept C192562407 @default.
• W3096473443 hasConcept C207001950 @default.
• W3096473443 hasConcept C2776572452 @default.
• W3096473443 hasConcept C2777077863 @default.
• W3096473443 hasConcept C2780740852 @default.
• W3096473443 hasConcept C55493867 @default.
• W3096473443 hasConcept C71924100 @default.
• W3096473443 hasConcept C86181022 @default.
• W3096473443 hasConcept C86803240 @default.
• W3096473443 hasConcept C98274493 @default.
• W3096473443 hasConceptScore W3096473443C126322002 @default.
• W3096473443 hasConceptScore W3096473443C150903083 @default.
• W3096473443 hasConceptScore W3096473443C155672457 @default.

• next